NCT07416461 Effectiveness of Malaria Vaccines in Reducing the Risk of Invasive Non-typhoidal Salmonella Disease
| NCT ID | NCT07416461 |
| Status | Recruiting |
| Phase | — |
| Sponsor | International Vaccine Institute |
| Condition | Invasive Non-Typhoidal Salmonella Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 10,000 participants |
| Start Date | 2025-10-27 |
| Primary Completion | 2027-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 10,000 participants in total. It began in 2025-10-27 with a primary completion date of 2027-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to learn about the impact of malaria vaccination on the risk of invasive non-typhoidal Salmonella disease in children below the age of 5. Eligible participants residing in the Kisantu Health Zone (DRC) and presenting fever are enrolled in healthcare facilities and tested for malaria and iNTS. Using a case-control (test-negative) design, the researchers will look at the malaria vaccination status of participants with and without iNTS infection to determine if the malaria vaccine protects against iNTS.
Eligibility Criteria
Inclusion Criteria: 1. Patients of all ages currently living in the catchment area of the health center presenting to healthcare facility with objective fever of at least 38.0°C tympanic or 37.5 °C axillary OR 2. Patients of all ages currently living in the catchment area of the health center presenting to healthcare facility with reported fever ≥3 consecutive days within 7 days of presentation
Contact & Investigator
Octavie Lunguya
PRINCIPAL INVESTIGATOR
Institut National de Recherche Biomedicale
Frequently Asked Questions
Who can join the NCT07416461 clinical trial?
This trial is open to participants of all sexes, studying Invasive Non-Typhoidal Salmonella Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07416461 currently recruiting?
Yes, NCT07416461 is actively recruiting participants. Contact the research team at Birkneh.Tadesse@ivi.int for enrollment information.
Where is the NCT07416461 trial being conducted?
This trial is being conducted at Kinshasa, Democratic Republic of the Congo.
Who is sponsoring the NCT07416461 clinical trial?
NCT07416461 is sponsored by International Vaccine Institute. The principal investigator is Octavie Lunguya at Institut National de Recherche Biomedicale. The trial plans to enroll 10,000 participants.